The Adaptive Experience

Almost half of clonoSEQ-tested patients receive the Clonality (ID) test using a fresh sample.

What types of samples are used for clonoSEQ testing in the real world?

clonoSEQ requires a high disease load sample from the time of diagnosis or relapse to identify (ID) which cancer-associated DNA sequence(s) to track. The Clonality (ID) test can be performed on either a fresh or an archived specimen. For ~45% of clonoSEQ-tested patients, the Clonality (ID) test is performed using a fresh sample*.  This suggests that many clinicians are seeking to get their patients “ready” for future MRD testing upfront, knowing that they will likely want to leverage MRD insights later in their patient’s treatment journey.

* Assumes ID collection date is indicative of time of diagnosis

AdaptiveExp 7 ALL
AdaptiveExp 7 MM
AdaptiveExp 7 CLL

This page is intended for use by healthcare professionals of the United States.

clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) , and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit

**Blood-based MRD testing for patients with B-Cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma is available as a CLIA-regulated laboratory developed test (LDT) service provided by Adaptive Biotechnologies. This use of clonoSEQ has not been approved or cleared by the FDA